ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies-Reference-Cited by-同舟云学术

ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies

Published:2018-03-08 Issue:10 Volume:131 Page:1094-1105
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Zammarchi Francesca¹,Corbett Simon²³,Adams Lauren²,Tyrer Peter C.²,Kiakos Konstantinos³,Janghra Narinder⁴,Marafioti Teresa⁴,Britten Charles E.¹,Havenith Carin E. G.¹,Chivers Simon¹,D’Hooge Francois²,Williams David G.²,Tiberghien Arnaud²,Howard Philip W.²,Hartley John A.¹²³,van Berkel Patrick H.¹

Affiliation:

1. ADC Therapeutics (UK) Limited, London, United Kingdom;

2. Spirogen/Medimmune Ltd, London, United Kingdom; and

3. Cancer Research UK Drug DNA Interactions Research Group and

4. Department of Pathology, University College London Cancer Institute, London, United Kingdom

Abstract

Key Points ADCT-402 is a CD19-targeted ADC delivering SG3199, a cytotoxic DNA minor groove interstrand crosslinking PDB dimer warhead. ADCT-402 has potent and selective antitumor activity against CD19-expressing hematological malignancies warranting clinical development.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/10/1094/1405649/blood813493.pdf

Reference34 articles.

1. CD19: a promising B cell target for rheumatoid arthritis;Tedder;Nat Rev Rheumatol,2009

2. Role of the CD19 and CD21/35 receptor complex in innate immunity, host defense and autoimmunity;Haas;Adv Exp Med Biol,2005

3. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy;Wang;Exp Hematol Oncol,2012

4. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy;Scheuermann;Leuk Lymphoma,1995

5. Monoclonal antibodies in acute lymphoblastic leukemia;Jabbour;Blood,2015

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ABBV-319: a CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies;Blood;2024-08-15

2. Engineering synthetic agonists for targeted activation of Notch signaling;2024-08-06

3. Pharmaceutical innovation and advanced biotechnology in the biotech-pharmaceutical industry for antibody–drug conjugate development;Drug Discovery Today;2024-08

4. Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies;MedComm;2024-07-28

5. Antitumor Activity of a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting LGR5 in Preclinical Models of Neuroblastoma;Pharmaceutics;2024-07-15